Recent News

• 08.04.2026 - Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
• 08.04.2026 - Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
• 07.22.2026 - Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
• 07.22.2026 - Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
• 07.21.2026 - Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
• 07.21.2026 - Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
• 07.07.2026 - Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
• 07.07.2026 - Akari Therapeutics Appoints Former AACR President andRenowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
• 06.29.2026 - Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
• 06.29.2026 - Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Recent Filings

• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.13.2026 - EFFECT Notice of Effectiveness
• 07.10.2026 - S-3/A Registration statement under Securities Act of 1933
• 07.08.2026 - S-3/A Registration statement under Securities Act of 1933
• 07.07.2026 - EFFECT Notice of Effectiveness
• 07.02.2026 - 8-K Current report
• 07.02.2026 - S-3 Registration statement under Securities Act of 1933
• 06.26.2026 - 8-K Current report
• 06.26.2026 - S-1/A General form for registration of securities under the Securities Act of 1933